In the midst of growing worldwide interest in medicinal cannabis, The Now Company (OTC: NWPN) is lighting up on Wall Street with serious profit potential ahead!
Cannabis is expected to heavily disrupt the pharmaceutical industry as patients all over the world continue to report on the medicinal benefits of the all-natural plant.
This may be the perfect time to start paying heavy attention to the sector and to The Now Company (OTC: NWPN), a bio-pharmaceutical research company that is focused on improving the health and wellness of patients worldwide and is building a dynamic, innovative and forward-looking research, development, education, and testing company serving the fast growing cannabis industry across the US and Canada.
With the 2018 Farm Bill that was passed in December 2018, industrial hemp in the United States became federally legalized.
This means that hemp is no longer regulated as an illegal substance under the US Justice Department and this is greatly benefiting the CBD industry.
According to New Frontier Data: China led all countries with nearly $1.2 billion USD in hemp sales in 2018, followed by the United States ($1.0 billion), Europe ($980 million) and South and Central America ($220 million).
The Now Corporation (OTC:NWPN) Starts Development Of A CBD-Infused Sports Cream
(Released October 2nd, 2020)
The U.S. market is positioned to grow under the 2018 Farm Bill, with an estimated $2.6 billion projected in sales by 2022, with $1.3 billion in sales estimated for hemp-derived CBD products by 2022!
According to the National Retail Federation, the CBD industry grew in customer demand by a whopping 700 percent in 2019.
CBD sales are also expected to reach $4 billion dollars by 2023 says the Nutrition Business Journal.
The public awareness of CBD and its many natural benefits is exploding and CBD products are flooding the market. As CBD becomes legal and more available throughout the US, increased government regulation is inevitable!
The Now Company (OTC: NWPN) is well positioned to capitalize on the emerging opportunities resulting from the need for more research studies, product testing, hemp cultivation and production, product development, and education!
This could mean an exciting ground-floor situation at current trading prices!
On November 19, 2019, The FDA warned 15 companies for illegally selling various
products containing cannabidiol as the agency details safety concerns.
Violations included marketing unapproved new human and animal drugs, selling CBD products as dietary supplements, and adding CBD to human and animal foods.
These are concerning issues that take place in the marijuana industry and through the company's research, The Now Company (OTC: NWPN) will address such safety concerns by performing rigorous testing of CBD compounds.
By publishing a scientific white paper based on the study, it will additionally allow the FDA to review the information and have credible data to make concrete rulings.
While the industry is big, safety concerns are still prevalent creating a demand for the type of research The Now Company (OTC: NWPN) is involved with.
One reason to closely follow The Now Company (OTC: NWPN) is because of big pharma...
Big pharma is definitely recognizing the very lucrative opportunity when it comes to medicinal marijuana.
Cannabis is inexpensive to produce, and with the right policies, there could be widespread access to those in need, which disrupts the traditional marketplace.
A recent report found that Big Pharma stands to lose as much as $4 billion per year if medical marijuana became legal in all 50 states. The information is based off a study from 2016 by the University of Georgia, which found that states with legalized medicinal cannabis had less Medicare prescriptions than those where it's still illegal.
The study found that already pharmaceutical companies are losing $166 million annually on drugs where marijuana is now offered as an alternative.
Big pharma will have no choice but to jump onto the cannabis bandwagon if they want to continue capitalizing on patients!
The Now Corporation (OTC:NWPN) Acquires 50% Of A Brand To Be Used To Sell CBD/Marijuana Products
(Released September 22nd, 2020)
GW Pharmaceuticals did and in the summer of 2018, Epidiolex became the first FDA-approved plant-derived cannabinoid medicine available by prescription in the U.S. to treat seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.
Epidiolex brought in $104 million in net sales in the fourth quarter and a total of $296 million in 2019 across the globe!
Pharmaceutical giants are already preparing for the cannabis revolution and are building connections. Plus with the rise in opioid lawsuits, it may lead to many drug companies looking to cannabinoids in the search for less-addictive pain relievers.
This will only further fuel the momentum of the cannabis revolution and these pharma giants could be going on shopping sprees to scoop up smaller players.
When investors look back on the cannabis industry a decade from now, they're liable to find one of the fastest growth trends on the planet and The Now Company (OTC: NWPN) could emerge as one of the biggest winners and acquisition targets!
The Now Company (OTC: NWPN) is a bio-pharmaceutical research company focused on the research, education and production of Scientific-Grade Cannabidiol (CBD) from hemp and Tetrahydrocannabinol (THC) to be used for medicinal purpose, while focusing on pursuing business opportunities in the growing medical and recreational marijuana sector.
Through its acquired assets, the company is seeking to invest in its businesses associated with the growing, marketing, research and development, training, distribution and retail sale of scientific-grade medicinal cannabis, both in the United States and Canada.
This includes, but is not limited to, food, paper, and textiles derived from Hemp.
The company additionally provides Credible Scientific Research Data to the heavily regulated medical and recreational marijuana industries - currently one of the fastest growing industries in North America.
The Now Company (OTC: NWPN) is unlocking and advancing medicine for human life around the world, at every stage of life!
WHO THEY ARE
The Now Company (OTC: NWPN) is dedicated to advancing the study of the medicinal use of Cannabidiol (CBD) and other cannabinoid molecules and seeks to develop cannabis-derived therapeutic products backed by strict and ethical scientific research.
In an effort to uncover the potential therapeutic capacity of cannabinoids, the company looks to establish the safest and most effective route of administration of highly purified CBD which currently remains to be determined within scientific literature.
The Now Company (OTC: NWPN) has the ability to grow and analyze hemp seed genetic variability, the source of CBD, and its relationship to potency, will aid the pursuit of effective dosing that will be required for maximal health benefits.
The Short Term Goal
The company has created agreements with top research scientists from major Universities and have utilized their existing labs to perform expensive research using cannabinoid compounds which are in cannabis plants.
From the research, the company will be able to publish research white papers that will contain credible data from these research laboratories.
As a result, the information that The Now Company (OTC: NWPN) publishes will start to establish increased credibility in the industry, and will allow the company's products to be prescribed by physicians since they will be able to access the information in their databases.
These studies will answer many questions and stop false data and rumors about CBD/THC derived from cannabis, and the effects on the human body.
The Long Term Goal
The company desires to have an FDA approved medicine that focuses on nausea and other ailments. Due to the FDA approval, it will be available for pharmacies to dispense, and will be on the approved list for insurance companies to pay for.
Ultimately, the company will pursue patenting the compound on a molecular level, similar to Pfizers patent on the drug, Viagra.
Nausea and vomiting are not diseases, but they are symptoms of many conditions such as: Motion sickness or seasickness. Early stages of pregnancy (nausea occurs in approximately 50%-90% of all pregnancies; vomiting in 25%-55%).
This makes the market for an anti-nausea medicine significant.
What Makes the Company Stand Out
The Now Company (OTC: NWPN) will have a scientifically tested product. The existing products that are available on the markets may not be safe.
For example, what is the safe dosing for CBDs in the human body? What is the effectiveness rate when humans consume CBD, and how much can a human take before it becomes toxic to the body?
The Federal government, along with State governments must find out this answer before deeming it safe. The company's research does not start at the plant, they will also research air, soil, and water, from a seed genetic level up to a mature plant.
CBD Drink Partnership
The Now Company (OTC: NWPN) owns 26% of Transglobal Assets Inc. (OTC:TMSH), which has a CBD drink. This partnership allows the company to validate and certify the product for its ingredients, and safety.
The company is extremely interested in Transglobal Assets' Monster Elixir subsidiary both as an investment and for additional synergies.
The Now Corporation (OTC:NWPN) Enters Into A Joint Venture With Hollywood Diagnostics Center For Human Imaging Diagnostics
(Released September 9th, 2020)
Monster Elixir Inc. will provide customers with a wide range of high-quality CBD products from its organically grown Indoor and Outdoor gardens. It uses some of the best genetics in the industry with a guarantee that its plants are free from all unwanted pests and harmful chemicals. Some other products are as follows:
Pur Root Lemonade: by utilizing the natural medicines in Marijuana Roots. Its Pur Root Lemonade will come in many flavors such as Ginger Bite and Pineapple Agave, sold in bulk or retail.
Infused Olive Oils: for all of your edible baking needs, it has Olive Oils Infused with CBDs, also sold in bulk or retail.
Distillates by the cartridges: Indica, Sativa and hybrids will be available.
Plus it will offer a unique arrangement of CBD Edibles, from hard candies and gummies to pound cakes and pies made from scratch.
These fine CBD products will be sold at local Dispensaries and other retail outlets, including at Monster Elixir stores coming soon.
Hemp Utilization and Research
The Now Company (OTC: NWPN) will continue to expand the ways in which hemp is utilized in industrial applications with crops grown from the State of North Dakota, under the Industrial Hemp Program.
The industrial hemp products being investigated include:
Bio-fuel derived from seeds
Hemp stalk/leaves for fiber material
Hemp root for medicinal purposes
The company has also established a joint venture in the Commonwealth of Puerto Rico with the goal of understanding and improving hemp plant biology.
Using a scientific approach, it seeks to research and produce hemp seeds with superior genetic characteristics, cultivated in an environmentally controlled greenhouse with filtered water and optimum nutrients.
The Now Company (OTC: NWPN) has an interest in the Hemp biofuel industry to provide a renewable alternative energy solution.
With respect to furtherance of this goal, the company looks to employ advanced chemistry research and technologies to elucidate the biological Hemp molecules to advance quality and effectiveness of the biofuel. North America has absolutely no problem extracting oil from Hemp seeds which the company can subsequently use to make biofuel.
The company has currently executed a joint venture in the US for the production of Industrial Hemp for the purpose of biofuel research and production in the State of North Dakota. The Industrial Hemp farming industry is capable of bringing the United States 100% clean, renewable energy!
"Our vision is clear, Industrial hemp is perfectly capable of fueling the modern world without displacing food or adding to the Greenhouse effect. We will embrace the research and development of a constant, safe and quality alternative energy. We live on this planet and need to do everything within our power to protect it so future generations can thrive.”
-CEO Ken Williams
In January The Now Company (OTC: NWPN) announced a pilot program for producing derivatives from Industrial Hemp for biodiesel fuel in North Dakota.
The NOW Biodiesel Pilot Program forms part of the existing joint venture agreement with Mr. Curtis Johnson, for the cultivation of Industrial Hemp to be grown near Grand Forks, North Dakota.
For the 2020 grow season, the pilot program will consist of 400 acres and, upon a successful growing season, the following years will then expand to include over 1000+ acres.
To Curtis Johnson who grew up on 2000 acres of a cattle and grain ranch, which he still owns and now grows soybeans, wheat and corn, this brings the opportunity for diversification and expansion of future cultivation:
“I am excited to start this pilot program with The Now Corporation and to expand and diversify cultivation of new highly demanded products. With current governmental approvals, the requirement of growing industrial Hemp utilizing this prime land is economically justified."
According to the U.S. Energy Information Administration*:
Production – U.S. production of biodiesel was 144 million gallons in October 2019. Biodiesel production during October 2019 was 2 million gallons higher than production in September 2019. Biodiesel production from the Midwest region (Petroleum Administration for Defense District 2) accounted for 68 percent of the United States total. Production came from 93 biodiesel plants with capacity of 2.5 billion gallons per year.
Sales – Producer sales of biodiesel during October 2019 included 57 million gallons sold as B100 (100% biodiesel) and an additional 84 million gallons of B100 sold in biodiesel blends with diesel fuel derived from petroleum.
The harvested biomass, pursuant to the joint venture, will undergo research and be quality tested for the effectiveness of hemp oil, and its blends for the purpose of fueling diesel engines. The end result will determine how the product would be economically and structurally feasible for use in further developing commercial biodiesel fuel.
The Now Company (OTC: NWPN) has signed a joint venture with Hollywood Diagnostics Center to perform neurological studies using state-of-the-art imaging technology to measure brain activity by detecting changes associated with blood flow when CBD compounds are introduced to the human body.
Hollywood Diagnostics Center is a leader in the medical diagnostics field while performing over 30,000 diagnostic procedures annually!
The center continues to be at the forefront of medical technology by progressively updating its equipment and procedures to reflect the latest advances in medicine. HDC has provided the healthcare community with outstanding, technologically advanced medical services to address the changing needs of patients.
The goal of the imaging data analysis is to detect correlations between brain activation in subjects when either non-tasked or tasked activities are performed during the scan with CBD compounds present.
It also aims to discover correlations with cognitive states after CBD compounds are introduced to the subject.
The data derived from the studies will be published to the public via the National Institute of Health (NIH) database or any other public platforms within the scientific research community.
The parties desire to establish between them a joint venture in order to collaborate in:
A) Independent industry reviews and studies (United States and internationally)
B) Analysis and research that measures brain activity by detecting changes associated with blood flow using cannabinoids to determine changes in brain function.
C) Perform blood draw findings that go along with imaging analyses.
D) Publishing of White Papers to National Institute of Health, and other Scientific Publishing Platforms.
The Now Company (OTC: NWPN) is aiming to work with both NASA and SpaceX for its research initiatives.
Concerning NASA, the company would like to utilize the International Space Station for unique discoveries of how CBD and THC reacts using animal testing. Cells tend to have a different effects in zero gravity.
Concerning SpaceX, they are aggressive in taking humans to space, for long extended times, and eventually to Mars. Through the company's research initiatives, the creation of an organic CBD nausea drug would be safe and beneficial for astronauts.
The Now Company (OTC: NWPN) has hired Jeffrey Watson as a hired consultant. Watson is a former housing official based in Miami.
Prior to joining the White House under the Clinton administration, he served as a Senior Administrative Assistant for the Mayor of Miami, Xavier Suarez.
In addition, he also served as Finance Administrator for the City of Miamis Department of Development and Housing Conservation Agency and then became an Interim Assistant and Deputy Assistant to the President for Intergovernmental Affairs in the Clinton Administration as well as serving as a Director of the Presidential transition team.
He served in various states as a State Field Director and ultimately Deputy National Field Director of the Clinton/Gore 1992 Presidential election campaign. At the White House, he coordinated the development of the Administration’s policy initiatives and facilitated communications between the White House and state and local government officials.
Meet the NWPN Team
Each member of the company's team is an experienced specialist in their field and together, they make sure investing in research is where the best returns are, while building loyalty across every touch point.
Ken Williams -- CEO and Managing Director
Ken Williams, CEO and Managing Director, also serves as Brand and Marketing Strategist. After spending five years leading public companies in the Legal Marijuana Industry, three decades of Advanced Technology Engineering, and as an Executive for multimillion dollar brands, Ken knows what truly drives business. It’s how well you connect with the public to help and communicate for understanding. Ken has excellent strategic planning and corporate execution skills. He works with major financial providers and bank brokerage firms on strategic initiatives including planning, clearing decisions, corporate changes and providers, and executes on new business opportunities.
Juan Salazar -- Chief Operating Officer
Juan Salazar, over the course of his career, has held senior and executive management positions with leading construction and development companies. He has a proven track record both at an operating and advisory level as a project manager, covering all stages of a construction from feasibility and engineering projects including technical reviews, project and financial evaluations to strategic planning, development, housing expansion, risk assessments and due diligence. Juan has extensive experience in agriculture and fish aquaponics forming a Florida-based corporation named Zorhek Aqua Farms in Miami, Florida.
David Krolewski, Ph.D. -- SENIOR CORPORATE RESEARCH ADVISOR
David is a systems neuroscientist with a particular interest in neuroanatomical function pertaining to human health and disease. This arena of study allows for analysis of particular molecules that affect brain function in relation to behavioral outcomes. After receiving a B.S. from Grand Valley State University in Health Science, he worked as a research technician at the Ann Arbor Veteran’s hospital where he assessed neurotransmitter transporter abundance in postmortem brain of people who died due to cocaine abuse. Following this experience, David went on to obtain a Ph.D. from Wayne State University Medical School where his research focused on Parkinson’s disease models and related neurocircuitry which regulate motor activity and its coordination. David’s postdoctoral fellowship was completed at the University of Michigan Medical School and involved the investigation of neuronal gene expression in postmortem subjects previously diagnosed with psychiatric disorders including major depression, bipolar disorder, and schizophrenia. Advancing to a research faculty member at the University of Michigan Medical School, he co-instructed an undergraduate human neuroanatomy course and continued examining neurogenetic changes in psychiatric illness by optimizing cutting edge histological techniques to visualize and quantify molecular changes in 3-dimensional formats.
Jeffrey B. Martin -- CHIEF TECHNOLOGY OFFICER
Jeff has 40 years of marketing, management and operational experience in a wide range of industries including management consulting, design engineering, environmental engineering and laboratory testing, and construction. He has held senior management positions in small private companies and large ($400 M+) publicly held enterprises. In addition to extensive marketing experience, Jeff has background in all corporate administrative functions having managed human resources, IT, contracts, safety, heavy equipment, risk and procurement departments. He has also successfully integrated numerous companies resulting from acquisitions and mergers in both union and non-union environments. Jeff holds an MBA from Northwestern University and a BS in Electrical Engineering and an MS in Nuclear Engineering from the University of Illinois.
Brian Martin -- CHIEF INNOVATION OFFICER
Brian has extensive experience in technology development, managing the implementation and operation of cutting-edge scientific technology in a research laboratory setting. His unique background as a research specialist has given him the technical expertise necessary for driving strategic innovation and identifying emerging market opportunities. Brian holds a Bachelor’s degree in Biochemistry and Molecular Biology with a focus on Biotechnology from Michigan State University.
Augustus Redmond -- DIRECTOR OF BUSINESS AND ECONOMIC DEVELOPMENT
Gus has over 35 years experience in Real Estate, Retailing, and Wholesale Industries. He has deep experience identifying and directing public/private joint ventures that are consistent with community objectives, including RFP solicitations, new initiatives, and revitalization efforts. He has extensive experience building rapport with businesses, property owners and real estates brokers. Gus has experience and background in Environmental Services including research, planning, and marketing of Wastewater, Solid Waste, and Hazardous Waste Recycling Systems for residential, commercial, and industrial applications.
The ignorant perception surrounding cannabis is continuing to fade. No longer is marijuana looked at as the stoner's legacy!
The reality is that this fascinating plant has the potential to reduce human and animal suffering on a magnificent level!
Cannabis is known for its medicinal qualities and health benefits that include relieving insomnia, anxiety, spasticity, and pain to even treating potentially life-threatening conditions such as diabetes, epilepsy, and cancer.
As more people become aware that there are many ways to use the plant for healing, the sentiment towards marijuana is expected to become even more favorable which could lead to legislation in many countries and even more U.S. states.
To date, 33 states and the District of Columbia regulate the production, sale, and use of marijuana and marijuana-infused products for medical purposes. Eleven of these states permit marijuana possession by adults while ten states also regulate adult-use sales.
Two-thirds of Americans now say the use of marijuana should be legal, reflecting a steady increase over the past decade, according to a new Pew Research Center survey.
More consumers are turning to marijuana with marijuana sales hitting records in many states even amid the COVID-19 pandemic. Across the country, sales are sky high in states where legal cannabis has been declared “essential medicine” during state shutdowns.
Members of the US House of Representatives are expected to vote later this month on The Marijuana Opportunity, Reinvestment, and Expungement Act... otherwise known as The MORE Act.
This is HUGE as it is the very first time that the U.S. House will vote on federal marijuana legalization!
"It's about time," Rep. Jerry Nadler told USA TODAY, calling it a "historic vote" marking the beginning of the end of the federal government's "40-year, very misguided crusade" against marijuana.
Pot stocks like The Now Company (OTC: NWPN) could be gearing up for a big rally as the U.S. finally pushes forward with federal marijuana legislation!
The Top 5 Reasons to Have The Now Company (OTC: NWPN) on Your Radar Right Now:
The company's CEO Ken Williams has spent five years leading public companies in the Legal Marijuana Industry, three decades of Advanced Technology Engineering, and as an executive for multi-million-dollar brands!
The U.S. is getting closer to federalizing marijuana on a federal level. The Federal government can't stick its head in the sand much longer and ignore the immense profit opportunity of the industry and the demands of the people. This could create an enormous rally for pot related stocks!
The company's scientifically tested products could capture a massive market with U.S. marijuana sales expected to top $30 billion in four years according to the 2020 "Marijuana Business Factbook."
Big pharma giants could be on acquisition sprees to get footing into the cannabis market and the company is focused on getting an FDA approved medicine that focuses on nausea and other ailments. As evidence of medical cannabis continues to mount, so does the industry of the global pharma industry. Big pharma has been watching from the sidelines but now that the industry is getting bigger than ever and the U.S. is headed towards federal legislation, takeover interest is intensifying!
The company is driving toward a greener future with hemp biofuels and could set to profit immensely as the world embraces the next generation of biofuels! Hemp biofuels could help lead the nation’s economy from a petroleum-based economy to a hemp-based economy.
As the legal marijuana industry evolves at a rapid pace and as interest in marijuana companies continues to grow, The Now Company (OTC: NWPN) looks poised to separate itself from all the rest...
https://www.civilized.life/articles/big- pharma-lose-billions-medical- marijuana/
https://norml.org/blog/2020/09/10/four- reasons-why-the-more-act-vote- is-a-really-big-deal/
https://www.usatoday.com/story/news/ politics/2020/09/04/marijuana-house -vote-federal- legalization-first-time/5678068002/
https://ir.gwpharm.com/news-releases/ news-release-details/epidiolexr- cannabidiol-oral-solution- first-fda-approved-plant
https://www.cnbc.com/2020/01/16/cbd- epilepsy-drug-does-incredible-296- million-in-sales-gw-pharma- ceo.html
https://www.pewresearch.org/fact-tank /2019/11/14/americans-support- marijuana-legalization/
https://www.cnbc.com/2020/03/25/legal -cannabis-industry-sees-record- sales-in-coronavirus- crisis.html
https://www.fool.com/investing/2020/07/ 21/4-cannabis-stocks-forecast- to-hit-1-billion-in- ann.aspx
https://www.webmd.com/digestive-disorders /digestive-diseases-nausea- vomiting#1
https://asdonline.com/blog/retail-news/ the-cbd-industry-surprising- changes-and-growth-due-to- covid-19/
https://www.newhope.com/market-data-and- analysis/analysts-take-mass- market-sales-hemp-cbd- projected-spike-2020
Disclaimer: Pursuant to an agreement between Electrik Dojo, CZA and DearWallstreet.com, we were hired to publicly disseminate information about (( NWPN )) including on the Website and other media including Facebook and Twitter. We were paid up to $130k in cash from Electrik Dojo. We own zero shares of (( NWPN )) which we purchased in the open market. We may buy or sell additional shares of (( NWPN )) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.